[
  {
    "ts": null,
    "headline": "Do Wall Street Analysts Like AbbVie Stock?",
    "summary": "Although AbbVie has underperformed the S&P 500 Index over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=20d945f0715b2c5242d44350c0d9c5f8a66dd2fa6e88dac2d4b2f033d2d31c2f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762198897,
      "headline": "Do Wall Street Analysts Like AbbVie Stock?",
      "id": 137312129,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Although AbbVie has underperformed the S&P 500 Index over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=20d945f0715b2c5242d44350c0d9c5f8a66dd2fa6e88dac2d4b2f033d2d31c2f"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Monday when compared to competitors",
    "summary": "AbbVie Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=b9aca2f2c27bdd14d20301f4dfd3980e4cde54ea875ee279786c0370c377d00e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762187460,
      "headline": "AbbVie Inc. stock underperforms Monday when compared to competitors",
      "id": 137317164,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=b9aca2f2c27bdd14d20301f4dfd3980e4cde54ea875ee279786c0370c377d00e"
    }
  },
  {
    "ts": null,
    "headline": "ABBV Q3 Deep Dive: Immunology Growth and Pipeline Expansion Offset Margin Pressure",
    "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 9.1% year on year to $15.78 billion. Its non-GAAP profit of $1.86 per share was 4.2% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=58d78fb31424627dd86cd81b1810dd196c8712aa5543fa8440aae9d570547488",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762180547,
      "headline": "ABBV Q3 Deep Dive: Immunology Growth and Pipeline Expansion Offset Margin Pressure",
      "id": 137305948,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Pharmaceutical company AbbVie (NYSE:ABBV) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 9.1% year on year to $15.78 billion. Its non-GAAP profit of $1.86 per share was 4.2% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=58d78fb31424627dd86cd81b1810dd196c8712aa5543fa8440aae9d570547488"
    }
  },
  {
    "ts": null,
    "headline": "Here’s What Drove Baron Health Care Fund to Add AbbVie (ABBV) to Its Portfolio",
    "summary": "Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund rose 5.39% (Institutional Shares) in the quarter, compared to a 5.05% gain for the Russell 3000 Health Care Index (benchmark) and an 8.18% gain for the Russell 3000 […]",
    "url": "https://finnhub.io/api/news?id=13ea5af89346fef59d9983d0327fedb2ec73b1bc258ede766a0b239dc0d31e4f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762179592,
      "headline": "Here’s What Drove Baron Health Care Fund to Add AbbVie (ABBV) to Its Portfolio",
      "id": 137302247,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund rose 5.39% (Institutional Shares) in the quarter, compared to a 5.05% gain for the Russell 3000 Health Care Index (benchmark) and an 8.18% gain for the Russell 3000 […]",
      "url": "https://finnhub.io/api/news?id=13ea5af89346fef59d9983d0327fedb2ec73b1bc258ede766a0b239dc0d31e4f"
    }
  },
  {
    "ts": null,
    "headline": "Analyst on AbbVie (ABBV): ‘Stay Long’",
    "summary": "We recently published 10 Stocks Everyone’s Discussing Amid Latest Earnings Season. AbbVie Inc. (NYSE:ABBV) is one of the stocks everyone’s discussing. Jason Snipe, the Founder and Chief Investment Officer of Odyssey Capital Advisors, recommended investors to “stay long” AbbVie Inc (NYSE:ABBV) during a recent program on CNBC. ABBV shares are up 21% so far this […]",
    "url": "https://finnhub.io/api/news?id=4d3a445a3ffd87f1d5477557725aa8e156d1d6682a3575d5f824c1b75a0bef8f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762176101,
      "headline": "Analyst on AbbVie (ABBV): ‘Stay Long’",
      "id": 137302248,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks Everyone’s Discussing Amid Latest Earnings Season. AbbVie Inc. (NYSE:ABBV) is one of the stocks everyone’s discussing. Jason Snipe, the Founder and Chief Investment Officer of Odyssey Capital Advisors, recommended investors to “stay long” AbbVie Inc (NYSE:ABBV) during a recent program on CNBC. ABBV shares are up 21% so far this […]",
      "url": "https://finnhub.io/api/news?id=4d3a445a3ffd87f1d5477557725aa8e156d1d6682a3575d5f824c1b75a0bef8f"
    }
  },
  {
    "ts": null,
    "headline": "My Favorite Dividend King to Buy in November",
    "summary": "This member of dividend royalty checks off lots of boxes for investors.",
    "url": "https://finnhub.io/api/news?id=46e39c1df5ff34974de3b432681c50c771292531d74bb5453b3e93b1801b6de3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762173000,
      "headline": "My Favorite Dividend King to Buy in November",
      "id": 137302249,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "This member of dividend royalty checks off lots of boxes for investors.",
      "url": "https://finnhub.io/api/news?id=46e39c1df5ff34974de3b432681c50c771292531d74bb5453b3e93b1801b6de3"
    }
  },
  {
    "ts": null,
    "headline": "United States Multiple Myeloma Market Research Report 2025-2033, Profiles of Key Players - Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, Takeda, and Bristol-Myers Squibb",
    "summary": "Opportunities in the U.S. multiple myeloma market include leveraging cutting-edge therapies like targeted treatments and immunotherapies, capitalizing on aging demographics, increasing disease awareness, and investing in oncology research. Expansion in combination treatments also offers significant potential. U.S. Multiple Myeloma Market U.S. Multiple Myeloma Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The \"United States Multiple Myeloma Market Size, Insights, Analysis, Growth Potential and",
    "url": "https://finnhub.io/api/news?id=2eadee4000155ed6b35aa4437da7c0e07a6decf3ae51676f37ee5680c157fe29",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762164720,
      "headline": "United States Multiple Myeloma Market Research Report 2025-2033, Profiles of Key Players - Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, Takeda, and Bristol-Myers Squibb",
      "id": 137302169,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Opportunities in the U.S. multiple myeloma market include leveraging cutting-edge therapies like targeted treatments and immunotherapies, capitalizing on aging demographics, increasing disease awareness, and investing in oncology research. Expansion in combination treatments also offers significant potential. U.S. Multiple Myeloma Market U.S. Multiple Myeloma Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The \"United States Multiple Myeloma Market Size, Insights, Analysis, Growth Potential and",
      "url": "https://finnhub.io/api/news?id=2eadee4000155ed6b35aa4437da7c0e07a6decf3ae51676f37ee5680c157fe29"
    }
  }
]